Bridgepoint and Triton walk away from Spire Healthcare (LSE: SPI) as board keeps formal sale process alive with remaining bidders

Spire Healthcare Group plc (LSE: SPI), the United Kingdom’s largest private hospital operator by revenue with 38 hospitals and more than 60 clinics across England, Wales, and Scotland, confirmed on 20 March 2026 that takeover discussions with private equity firms Bridgepoint Advisers Limited and Triton Investment Advisers have formally ended. Both bidders had been at the centre of a six-month formal sale process that Spire’s board launched in September 2025 under pressure from shareholders frustrated by a prolonged share price decline. The departures leave the strategic review in a materially narrower position than it was in January, when multiple parties were reported to be actively engaged with the company’s financial advisers at Rothschild. Spire shares closed at around 145p on 24 March 2026, near the lower end of their 52-week range of 143p to 257p, reflecting the market’s sceptical read on what remains of a process that once carried a rumoured valuation of up to £1.5 billion.

Why did Bridgepoint withdraw from the Spire Healthcare takeover process at the final deadline?

Bridgepoint’s departure was the more consequential of the two exits, arriving just as Sky News had reported the firm was finalising proposals for a formal offer at approximately 230p per share, which would have valued Spire at around £1 billion. In its official statement, Bridgepoint said it had been unable to achieve sufficient confidence regarding a transaction structure that would work for all stakeholders. The language is careful but pointed: the problem was not the price or the quality of the asset, but the mechanics of a deal that could satisfy Spire’s institutional shareholder base, its NHS contractual obligations, its freehold property estate, and the capital structure requirements of a leveraged buyout simultaneously.

Triton’s exit was more abrupt. The firm issued a brief Rule 2.8 statement confirming it does not intend to make a firm offer, offering no elaboration. Taken together, the twin withdrawals suggest that the complexity of structuring a private equity acquisition of a business with Spire’s combination of NHS revenue dependency, substantial property assets, pension obligations, and listed-company governance requirements may have exceeded what either buyer could price with confidence at the current valuation level.

Notably, both Bridgepoint and Triton retain the right under Rule 2.8 of the City Code on Takeovers and Mergers to re-engage within six months of their respective withdrawal announcements, provided specific conditions are met, including if a third party announces a firm intention to make an offer. That carve-out keeps the door technically ajar, though re-entry within the review window would require Takeover Panel consent or a significant change in circumstances.

What does the Spire Healthcare strategic review process look like after Bridgepoint and Triton exit?

Spire’s board confirmed in its 20 March announcement that discussions with other unnamed parties remain ongoing and that it continues to evaluate other appropriate actions to drive long-term, sustainable shareholder value. The company remains in a formal offer period under the City Code, which means dealing disclosure requirements continue to apply across significant shareholders and other market participants. The fact that the board has chosen not to terminate the strategic review entirely is meaningful: it signals that at least one additional party remains in active dialogue, even if the composition of that remaining field is unknown.

Earlier in the process, reports named Advent International and Bain Capital as firms that had at least made contact with Rothschild, though both were described as unlikely to advance to formal bids. Potential trade buyers such as Mediclinic International and Circle Health Group had also been cited in analyst commentary at the time the review was launched, with some estimates placing a full trade sale valuation in the range of 325p to 450p per share. At today’s share price of around 145p, the gap between current market pricing and those earlier estimates is striking and suggests the investor community has largely priced out a near-term deal at any meaningful premium.

How does Spire Healthcare’s NHS revenue outlook complicate any private equity transaction structure?

NHS revenue accounts for approximately 30% of Spire’s hospital revenues, a proportion that introduces significant contracting risk into any leveraged acquisition model. In its most recent financial update, Spire disclosed that NHS commissioning revenues in the first quarter of 2026 are expected to fall by around 25% compared with the same period a year earlier, driven by cessation of NHS activity at several sites. The company flagged material uncertainty around committed funded activity for the 2026/27 NHS financial year, which resets in April. That uncertainty sits awkwardly in a financial model designed to support acquisition debt.

Private healthcare, which represents approximately 70% of hospital revenues, has continued to show momentum in recent months. Spire’s adjusted EBITDA for 2026 is expected to remain broadly in line with 2025 levels, which provides some floor for valuation discussions. However, the dual headwind of rising National Insurance costs, following the UK government’s Autumn 2025 Budget, and the step-down in NHS income introduces earnings volatility that creates genuine friction in pricing a takeover premium with confidence. A private equity buyer seeking to extract value through leverage and operational improvement needs earnings predictability; Spire’s current NHS exposure works against that requirement.

Could Spire Healthcare’s freehold property portfolio unlock value outside a full corporate sale?

One of the central arguments for a strategic transaction since the review was announced in September 2025 has been the company’s freehold property estate, which carries an estimated value of approximately £1.4 billion, materially above the company’s current market capitalisation of under £600 million. That gap has been a persistent source of shareholder frustration and sits at the heart of the board’s stated commitment to evaluating other appropriate actions to drive long-term, sustainable shareholder value. A sale-and-leaseback of all or part of the property portfolio, a demerger of real estate assets into a listed vehicle, or a partial monetisation through a real estate investment trust structure are among the options that fall within that framing.

The appeal of a property-led value release is that it does not require a full corporate sale, avoids the NHS contracting complications that appear to have troubled private equity bidders, and could return cash to shareholders without a change of control. The execution risk is real: a sale-and-leaseback at scale introduces long-term rent obligations that would affect future operating margins and financial flexibility. Investors in this type of structure would need to be satisfied that Spire’s operating income can comfortably service the resulting lease commitments. That confidence is harder to build at a time when NHS revenues are contracting and cost pressures from wage mandates remain elevated.

How does the failed 2021 Ramsay Health Care bid inform the current Spire Healthcare sale process?

Spire’s history with M&A processes is instructive context. In 2021, Australia’s Ramsay Health Care tabled a recommended offer at 240p per share, valuing the business at approximately £1 billion. The deal was rejected by shareholders who argued the price was inadequate given the underlying property value. Ramsay ultimately walked away after institutional resistance proved insurmountable. Five years later, Spire’s share price is languishing below 150p and the process that was expected to deliver materially higher bids has instead seen its two most prominent suitors withdraw at the put-up-or-shut-up deadline. The 2021 shareholders who refused 240p are now sitting on a stock that trades roughly 40% below that level, a trajectory that sharpens the board’s urgency in finding a resolution.

The parallel matters for two reasons. First, it sets a pricing anchor: any credible offer will need to offer a meaningful premium to current levels while framing itself relative to the earlier rejected bid, a context that creates awkward expectations on all sides. Second, it underscores that Spire’s shareholder register, which includes institutions who held through the 2021 process, may have a differentiated view of acceptable value versus where the market is currently pricing the stock. Whether that creates facilitative or obstructive conditions for the remaining bidders depends entirely on what price can be assembled.

What is the market pricing in for Spire Healthcare after the Bridgepoint and Triton withdrawals?

Spire’s shares closed at approximately 145p on 24 March 2026, a decline from the brief peak of around 192p recorded in early trading on 20 March, when Sky News reported that Bridgepoint was finalising bid proposals. The stock had earlier touched intraday levels above 190p on the back of that report before retreating sharply once both Bridgepoint and Triton confirmed they were standing down. The 52-week range of 143p to 257p captures the full arc of the strategic review premium and its subsequent deflation, with the stock now sitting just above its 52-week low.

Analyst consensus target prices remain significantly above current trading levels, suggesting the broker community retains a base case that some form of value realisation is achievable, whether through a sale at a premium, a property transaction, or a combination. However, consensus targets reflect assumptions about processes that are still live; the risk is that if the remaining discussions also terminate without a transaction, Spire’s share price could face meaningful further downside toward levels that better reflect standalone operating fundamentals rather than takeover optionality. The stock’s beta near zero means it moves largely on company-specific news, which makes the next announcement from the board the dominant variable for investors.

Key takeaways: What Bridgepoint and Triton’s exit means for Spire Healthcare shareholders and the UK private healthcare sector

• Bridgepoint and Triton have both formally withdrawn from Spire Healthcare’s sale process, with Bridgepoint citing an inability to achieve sufficient confidence in a workable transaction structure for all stakeholders.
• Spire’s board has confirmed the strategic review remains live with other unnamed parties still in discussions, and the company remains in a formal offer period under the City Code.
• The share price at around 145p sits near its 52-week low, down sharply from the 192p peak hit when a Bridgepoint bid appeared imminent, signalling the market has largely discounted near-term deal completion.
• Bridgepoint retains the right to re-engage within six months under Rule 2.8 carve-outs, a provision that preserves optionality without creating expectation of return.
• NHS revenue uncertainty, including a projected 25% first-quarter decline in NHS commissioning income and unconfirmed 2026/27 activity volumes, appears to have been a material complicating factor in structuring a leveraged acquisition.
• The £1.4 billion freehold property estate remains the primary source of embedded value not reflected in the current market capitalisation of under £600 million, and a property-led transaction outside a full corporate sale remains a credible path.
• The 2021 Ramsay Health Care precedent, where shareholders rejected a 240p recommended bid, remains a live reference point that complicates the pricing expectations of both the board and any remaining bidder.
• Private healthcare revenues, representing roughly 70% of hospital income, continue to grow, providing some operating resilience even as NHS income contracts.
• If all remaining discussions also terminate without a transaction, Spire faces the prospect of managing a re-rating toward standalone fundamental value, which would likely require an independent operational and capital allocation plan.
• The process highlights the structural challenges facing UK private hospital operators in attracting leveraged buyout capital given their dual exposure to regulated NHS contracting and property-intensive balance sheets.